![]() Upon closing of the transaction, Silverback will be renamed ARS Pharmaceuticals, Inc. Pursuant to amendment, Parent Net Cash, as finally determined pursuant to Section 1.6, shall not be less than $210,000,000 nor greater than $265,000,000 provided, however, that if Parent Net Cash is greater than $265,000,000, Parent may declare a Permitted Dividend in the amount of such excess to satisfy such condition. Upon stockholder approval, the combined company is expected to operate under the name ARS Pharmaceuticals and trade on the Nasdaq Capital Market under the ticker symbol SPRY. Upon closing, Silverback equity holders are expected to own approximately 37% of the combined company and pre-merger ARS equity holders are expected to own approximately 63% of the combined company on a fully-diluted basis. As of October 25, 2022, Silverback Therapeutics and ARS Pharmaceuticals entered in to second amendment. Pursuant to which a wholly owned subsidiary of Silverback will merge with and into ARS Pharma, with ARS Pharma surviving as a wholly owned subsidiary of Silverback (the Merger). As of August 11, 2022, Silverback Therapeutics and ARS Pharmaceuticals entered in to first amendment. The combined company is expected to have approximately $265 million in cash, cash equivalents and marketable securities at closing. As of November 2, 2022, the final Exchange Ratio will be 1.1819. At the effective time of the Merger, each outstanding share of common stock of ARS Pharma will be converted into the right to receive approximately 1.2441 shares of common stock of Silverback. ARS will merge with Silverback in an all-stock transaction. ![]() from a group of shareholders for approximately $270 million in a reverse merger transaction on July 21, 2022. entered into a definitive agreement to acquire Silverback Therapeutics, Inc. (NasdaqGM:SBTX) from a group of shareholders in a reverse merger transaction on June 10, 2022. executed the letter of intent to acquire Silverback Therapeutics, Inc. Since our founding in 2016, we have raised $47.5 million in venture capital from OrbiMed, Celgene Corporation, and Alexandria Venture Investments.ARS Pharmaceuticals, Inc. Silverback is based in the vibrant South Lake Union neighborhood in Seattle, Washington, where our multi-disciplinary team is rapidly advancing our lead programs toward clinical trials in multiple indications. At the core of our pipeline is our proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically administered to patients but that act only at the sites of disease, sparing healthy tissues from unwanted side effects.Īrmed with this technology, we believe that it is finally possible to overcome some of the biggest barriers to creating effective and enduring treatments for cancer, fibrosis, infectious diseases, and other devastating conditions. Our team brings together diverse perspectives and deep experience in drug discovery and development, allowing us to approach long-standing challenges in new ways. ![]() We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness ? until now. Silverback Therapeutics is charting a new path for treating a range of severe diseases. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |